Two Sigma Advisers LP Buys New Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Two Sigma Advisers LP bought a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 42,300 shares of the company's stock, valued at approximately $797,000. Two Sigma Advisers LP owned about 0.09% of Pacira BioSciences at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in PCRX. Charles Schwab Investment Management Inc. boosted its position in shares of Pacira BioSciences by 16.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company's stock valued at $9,462,000 after acquiring an additional 70,307 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Pacira BioSciences by 30.2% during the fourth quarter. ProShare Advisors LLC now owns 16,003 shares of the company's stock valued at $301,000 after purchasing an additional 3,710 shares in the last quarter. Empowered Funds LLC grew its stake in shares of Pacira BioSciences by 5.1% in the 4th quarter. Empowered Funds LLC now owns 229,485 shares of the company's stock valued at $4,323,000 after purchasing an additional 11,149 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Pacira BioSciences by 3.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company's stock valued at $491,000 after purchasing an additional 794 shares during the period. Finally, LPL Financial LLC acquired a new position in shares of Pacira BioSciences in the 4th quarter worth approximately $251,000. Institutional investors and hedge funds own 99.73% of the company's stock.

Pacira BioSciences Price Performance

PCRX traded down $0.28 during midday trading on Thursday, hitting $26.70. The company had a trading volume of 261,369 shares, compared to its average volume of 968,567. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $31.13. The company has a market capitalization of $1.24 billion, a PE ratio of -13.15 and a beta of 0.56. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The firm's 50-day simple moving average is $25.45 and its 200-day simple moving average is $23.19.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. HC Wainwright boosted their price target on Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research note on Tuesday, April 8th. Barclays boosted their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Finally, Needham & Company LLC lowered their target price on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, Pacira BioSciences currently has an average rating of "Hold" and a consensus price target of $26.44.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.